Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
Repare Therapeutics Inc. is focusing on advancing its clinical-stage oncology programs, including lunresertib, camonsertib, RP-1664, and RP-3467, with upcoming clinical milestones and potential near-term registration-enabling studies. The company plans to reduce its workforce by 25% and expects to extend its cash runway into the second half of 2026.
Reference News
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
Repare Therapeutics Inc. is focusing on advancing its clinical-stage oncology programs, including lunresertib, camonsertib, RP-1664, and RP-3467, with upcoming clinical milestones and potential near-term registration-enabling studies. The company plans to reduce its workforce by 25% and expects to extend its cash runway into the second half of 2026.